Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Performance of serum lipocalin 2 as a diagnostic marker for colorectal cancer|
|Citation:||Cancer Biomarkers, 2013; 13(2):75-79|
|Kim Y.C. Fung, Ilka Priebe, Leanne Purins, Bruce Tabor, Gemma V. Brierley, Trevor Lockett, Edouard Nice, Peter Gibbs, Jeannie Tie, Paul McMurrick, James Moore, Andrew Ruszkiewicz , Antony Burgess and Leah J. Cosgrove|
|Abstract:||Background: Lipocalin 2 has been implicated in colorectal tumorigenesis but its usefulness as a diagnostic marker for the disease has previously never been determined. Methods: We have used ELISA immunoassay to measure the level of serum lipocalin 2 in a cohort consisting of colorectal cancer patients (n=196) and age/gender matched controls (n=99). Results: The median concentration of lipocalin 2 was found to be significantly higher (p< 0.0001) in the patient group (105.9 ng/mL, range 10.8-444.7 ng/mL) when compared to the control subjects (86.4 ng/mL, range 17.1-190.0 ng/mL). Additionally, no significant difference was observed between disease stage (Dukes' or T stage) in the patient cohort. Receiver operating characteristic analysis was performed to determine its performance as a diagnostic marker. The area under the curve was found to be 0.641 (95% confidence interval 0.576-0.706). Furthermore, the sensitivity of lipocalin 2 was found to be 24% at 90% specificity. Conclusions: Our study indicates that lipocalin 2 is not a suitable serum biomarker for the diagnosis of CRC.|
|Keywords:||Colorectal cancer; biomarker; blood; diagnosis; lipocalin 2|
|Rights:||© 2013 – IOS Press and the authors. All rights reserved|
|Appears in Collections:||Medicine publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.